In Boon for Big Pharma, TTIP Would Lock In High Drug Prices

As E.U. and U.S. officials meet in New York this week for the 15th round of Transatlantic Trade and Investment Partnership (TTIP) negotiations, a new report warns of how the corporate-friendly, increasingly unpopular deal could "lock in" high drug prices and "help entrench a broken medical innovation system." Specifically, the analysis explains how expanding intellectual property rules and monopoly protections for medicines, which the TTIP seeks to do, is counterproductive at a time when E.U. member states and the U.S. "are facing a looming access to medicines crisis."

http://www.commondreams.org